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Summary
Background: The use of preparations from Bryophyllum pinna-
tum for tocolysis (or to arrest labor) is supported by observa-
tions obtained mainly at empirical level, but also by preclinical 
experiments performed with uterus strips and myometrium cell 
lines. Furthermore, a retrospective matched-pair study revealed 
good tolerability and effectiveness. In anthroposophic medi-
cine, however, Bryophyllum species are used for a broad spec-
trum of diagnoses. Here, we characterize the prescribing pat-
tern of Bryophyllum preparations in a network of anthropo-
sophic physicians in Germany. Methods: 38 primary-care phy-
sicians in Germany participated in the EvaMed network, a 
multi-center observational study. They documented ano-
nymized prescriptions, diagnoses and demographic data (age 
and gender) for each consecutive patient between 01.01.2004 
and 01.01.2010. Diagnoses were coded according to the 10th 
revision of the International Classification of Diseases (ICD-10). 
In the present analysis, all prescriptions of any Bryophyllum 
preparation in the resulting data bank were identified and the 
corresponding diagnoses were analyzed retrospectively. Re-
sults: A total of 4,038 prescriptions of Bryophyllum prepara-
tions were identified in the EvaMed data bank. A variety of 
preparations could be found, 77.7% of which were prepared 
from Bryophyllum plants exclusively and 22.5% were combina-
tions. Bryophyllum preparations were often prescribed to treat 
‘mental and behavioral disorders’ (ICD-10 F00–F99, 35.7%) and 
‘diseases of the skin and subcutaneous tissue’ (L00–L99, 
16.0%), followed by ‘symptoms, signs, and abnormal clinical 
and laboratory findings, not elsewhere classified diseases’ 
(R00–R99, 15.2%) and ‘diseases of the nervous system’ (G00–
G99, 9.7%). Conclusion: By revealing the use of Bryophyllum 
preparations in so many other indications than preterm deliv-
ery, our data clearly show the urgent need to conduct addi-
tional clinical trials.
Schlüsselwörter
Bryophyllum · Kalanchoe · Anthroposophische Medizin · 
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Zusammenfassung
Hintergrund: Die Anwendung von Bryophyllum-Präparaten in 
der Behandlung von vorzeitigen Wehen wird hauptsächlich von 
empirischen Beobachtungen und von experimentellen Ergeb-
nissen gestützt, die sowohl auf Organ- als auch auf Zellebene 
erzielt wurden. Darüber hinaus zeigte eine retrospektive 
 Matched-pair-Studie gute Verträglichkeit und Wirksamkeit. Da-
neben werden in der anthroposophischen Medizin Bryophyl-
lum-Arten für ein großes Spektrum von Erkrankungen einge-
setzt. In dieser Arbeit wurde das Verordnungsmuster von Bryo-
phyllum-Präparaten in einem Netzwerk anthroposophischer 
Ärzte in Deutschland charakterisiert. Methoden: 38 Hausärzte in 
Deutschland nahmen am EvaMed-Netzwerk, einer multizentri-
schen Anwendungsbeobachtung, teil. Zwischen dem 01.01.2004 
und dem 01.01.2010 erfassten sie für jeden konsekutiven Patien-
ten anonymisierte Verordnungen, Diagnosen und demographi-
sche Daten (Alter und Geschlecht). Die Diagnosen wurden nach 
ICD-10 (10. überarbeitete Auflage der International Classification 
of Diseases) codiert. In der vorliegenden Arbeit wurden retros-
pektiv aus der daraus resultierenden Datenbank alle Verordnun-
gen von Bryophyllum-Präparaten identifiziert und die zugehöri-
gen Diagnosen analysiert. Ergebnisse: Aus der EvaMed-Daten-
bank wurden 4038 Verordnungen von Bryophyllum-Präparaten 
identifiziert. Darunter fand sich eine Vielzahl an Präparaten, 
77,7% davon waren reine Bryophyllum-Präparate und 22,5% 
Kombinationspräparate. Bryopyhllum-Präparate wurden häufig 
für die Behandlung von «Psychischen und Verhaltensstörun-
gen» (ICD-10 F00–F99, 35,7%) und «Krankheiten der Haut und 
der Unterhaut» (L00–L99, 16,0%), gefolgt von «Symptomen und 
abnormen klinischen und Laborbefunden, die anderenorts nicht 
klassifiziert sind» (R00–R99, 15,2%) und «Krankheiten des Ner-
vensystems» (G00–G99, 9,7%) verordnet. Schlussfolgerung: Die 
Daten zeigen eine vielfältige Verordnung von Bryophyllum-Prä-
paraten bei anderen Indikationen als bei vorzeitigen Wehen und 
legen dadurch die dringende Notwendigkeit nahe, zusätzliche 
klinische Studien durchzuführen.
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medical expertise in the field of anthroposophic medicine. Ac-
cording to this commission, Bryophyllum preparations are to 
be used for the following indications [17]: vulnerability to spe-
cific types of functional disorders and recurring infections re-
lated to the metabolic system, preterm and early contractions, 
and in emergency situations of anxiety or other related mental 
problems and associated sleep disorders. In addition, some of 
the multiple combinations with Bryophyllum preparations are 
indicated for mood disorders, agitation, menopausal symp-
toms, premenstrual syndrome, obsessive-compulsive disorders, 
prostration, and shock consequences [17]. There are several 
similarities between these indications and those suggested in 
another reference work on anthroposophic medicine [18], 
namely situations of agitation/anxiety, sleeping disorders, 
asthma, psychosomatic disorders, psoriasis, and neurodermitis. 
Anthroposophic physicians frequently rely on these 2 refer-
ence works to choose their anthroposophic medications, but it 
is not known whether these sources were also used by the phy-
sicians participating in the present study (see below).
The Evaluation of Anthroposophic Medicine (EvaMed) 
network aimed to evaluate the use of remedies from comple-
mentary and alternative medicine (CAM) in primary care 
with regard to prescribing patterns, efficacy, and safety [19–
24]. 38 German physicians participated in this network by 
 entering patient data on age, gender, diagnosis, and treat-
ments. The resulting data bank has been / is being used to 
 determine which remedies are being prescribed in general 
[19], which ones are prescribed for a certain diagnosis or 
group of diagnoses [20, 24], for a defined patient group [22, 
23], and in order to characterize the prescribing pattern of a 
particular group of remedies [21].
Until the present work, it was not known for which exact 
diagnoses Bryophyllum preparations are being prescribed in 
daily clinical practice in Germany. In this country, Bryophyl-
lum preparations can be obtained over-the-counter and have 
been in some cases officially authorized and in others regis-
tered, always without specific indications. In this work, the 
EvaMed data bank was used retrospectively to characterize 
the prescribing pattern of preparations based on Bryophyllum 
plants. It is expected that this knowledge will help in design-
ing future clinical studies to address the effectiveness of the 
treatment of other disorders than preterm contractions.
Methods
Physicians were recruited among the members of the German National 
Association of Anthroposophic Physicians (Gesellschaft Antroposo-
phischer Ärzte in Deutschland; GAÄD), which implies that all of them 
were specialized in anthroposophic medicine. A total of 362 physicians 
were contacted and informed about the EvaMed network by standard 
mail and, in the event of no response, 4 weeks later by telephone. For a 
physician to be eligible to participate in the study, he/she had to have a 
minimum of 5 years of professional experience and his/her medical prac-
tice had to meet a number of technical requirements, such as the presence 
of a special computerized patient documentation system (DocExpert, 
Introduction
Bryophyllum spp. have been used in ethno-medicine of the 
regions of origin – tropical Africa, tropical America, India, 
China, Australia [1] – for a long time and apparently with con-
siderable success. In their countries of origin, leaves of these 
plants are used to treat jaundice [2], inflammation, infections 
[3], and hypertension, as well as bladder and kidney problems 
[4]. Furthermore, there are indications that extracts from 
leaves of plants of the genus Bryophyllum (family Crassu-
laceae) might have the following properties [1]: analgesic, 
antipyretic, sedative, central nervous system (CNS) depres-
sant, muscle relaxant, gastroprotective, anti-inflammatory, 
 antiseptic, anti-allergic, anti-anaphylactic, antileishmanial, an-
titumor, anti-ulcer, immunomodulating, and wound healing 
(see also [3, 5–7]). Finally, extracts of whole plants have been 
shown to have hypoglycemic properties, which might be use-
ful in the treatment of diabetes [6].
In Europe, the use of remedies prepared from the species 
Bryophyllum is limited almost exclusively to anthroposophic 
medicine, a holistic medical system founded by Rudolf Steiner 
and Ita Wegman in the 1920s [8]. There are several different 
Bryophyllum preparations currently in use that are produced 
either from Bryophyllum pinnatum (Lamarck) Oken (syno-
nym: Kalanchoe pinnata (Lamarck) Persoon), synonym: Bryo-
phyllum calycinum (Salisbury) or from Bryophyllum daigre-
montianum (Hamet and Perrier) Berger (synonym: Kalanchoe 
daigremontiana Hamet and Perrier). To our knowledge, the 
only clinical trials performed so far with Bryophyllum prepa-
rations address their use in the treatment of women with pre-
term labor, i.e. for tocolysis [9]. The first studies suggesting 
that B. pinnatum could show good tolerability and effective-
ness had several methodological limitations [10–12]. Later on, 
the effectiveness and tolerability of an aqueous extract of 
B. pinnatum leaves were compared with those of betamimet-
ics, in a retrospective study in which data of patients with pre-
term contractions treated with B. pinnatum were matched with 
data of comparable patients treated with beta-agonists [13]. 
While the effectiveness was similar, B. pinnatum led to signifi-
cantly fewer side effects. The use of preparations from B. pin-
natum in the treatment of premature labor was supported by 
experiments performed first with a leaf aqueous extract using 
uterus strips [14], and thereafter conducted with press juice of 
leaves both at organ [15] and at cell level [16], always using 
experimental models that mimic uterus contractions in vitro.
Within anthroposophic medicine, the indications for which 
a given plant preparation is prescribed derive from hypotheses 
concerning the pathophysiological processes occurring in the 
human being and the physiological processes taking place in 
the plant. Depending on the part of the plant used to produce 
the preparation and on the pharmaceutical methods, the sug-
gested indications can be different. In Germany, a commission 
was constituted to support the work of the Federal Institute 
for Medicinal Products and Medical Devices by providing 
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used a browser-based interface to match individual diagnoses with the cor-
responding drugs or remedies that had been prescribed. Finally, study in-
vestigators checked the data for completeness (e.g., matching diagnoses 
with remedies). If necessary, the study center phoned the physicians and 
asked them to supply any missing data. Diagnoses were coded according 
to the 10th revision of the International Classification of Diseases (ICD-
10). Prescribed drugs were documented using the German National Drug 
Code (German: Pharmazentralnummer; PZN). The data collection cov-
ered the period from January 2004 until January 2010 (6 years).
The present retrospective analysis is based on the EvaMed data bank. 
Prescriptions were included in this analysis if Bryophyllum or one of the 
corresponding national codes was mentioned and if under therapy at least 
1 diagnosis was mentioned. Subgroup analyses were performed for patient 
gender, age (younger than 12 years, 12–29 years, 30–44 years, 45–59 years, 
60–79 years, 80 years or older), as well as for the various Bryophyllum 
preparations. Statistical analysis was performed with SPSS 16.0 for Win-
dows. Descriptive analysis was used to determine prescription rates. 
Means and standard deviations (SDs) were calculated for continuous data.
Results
Description of the Participating Physicians and Patients
A total of 4,038 prescriptions of various Bryophyllum prepa-
rations were identified (table 1), corresponding to 2,280 pa-
tients; these were on average 29.5 ± 22.27 years old and in 
DocConcept, TurboMed, Duria, AdamedPlus, Medistar), a local area 
network (LAN) connection, and Microsoft Windows and Internet Ex-
plorer (i.e., as client software).
A total of 38 physicians (10.5% of the physicians contacted, 6.3% of 
the approximately 600 physicians in GAÄD) fulfilled the various require-
ments, gave informed consent, and agreed to participate in this prospec-
tive, multicenter observational study. All of them became members of the 
EvaMed network, which aims to evaluate CAM remedies in usual care 
with regard to prescribing patterns, efficacy and safety [19, 22–24]. The 
participating physicians were from 12 of 16 German states, their average 
age was 48.0 ± 6.1 years and 55% of them were male; none was working 
in a health center. They prospectively documented anonymized prescrip-
tions, diagnoses and demographic data (age and gender) for each consec-
utive patient and provided these administrative, secondary data to the 
EvaMed data bank. The recommendations for good practice in secondary 
data analysis (e.g. anonymization of data on prescriptions and diagnoses) 
developed by the German Working Group on the Collection and Use of 
Secondary Data [25] were applied in full. In addition, the study was ap-
proved by the data security office of the Community Hospital Havel-
hoehe, which is associated with the Havelhoehe Research Institute. As 
only administrative, anonymized data were used and no experimental re-
search or intervention on patients was applied, no ethical approval was 
considered to be needed [26].
Prescriptions for each consecutive patient were entered in the data set 
by the participating physicians using their existing computerized patient 
documentation system. These data were thereafter exported to the Qual-
ity Documentation Statistics System in Health Care (QuaDoSta) hosted in 
each practice [20]. After completing each export, participating physicians 
Number Percentage
Bryophyllum species
B. pinnatum 3,830 94.8
B. daigremontianum  208  5.2
Bryophyllum monopreparationsa
Bryophyllum (50% powderb)* 1,063 26.3
Bryophyllum Argento cultum Rh (D3 aqueous dilutions)* 1,049 26.0
Bryophyllum Argento cultum (alcoholic dilutionsc)*  693 17.2
Bryophyllum (alcoholic dilutionsd of the mother tincture)*  135  3.3
Bryophyllum Argento cultum Rh (aqueous dilutionsc for injections)*   47  1.2
Bryophyllum (5% aqueous solutions for injectionse)*   43  1.1
Bryophyllum Mercurio cultum (alcoholic dilutionsc)*   40  1.0
Bryophyllum Rh (D3 aqueous dilutions)*   39  1.0
Bryophyllum Mercurio cultum Rh (D3 aqueous dilutions)*   24  0.6
Bryophyllum combinations
Bryophyllum D5/Conchae D7 (aqueous dilutions for injections*  687 17.3
Bryophyllum comp Globuli velati**  140  3.5
Bryophyllum comp (aqueous dilutions for injections)**   68  1.7
Dilutions
D1–D3 2,293 54.2
50% 1,063 26.3
D5–D10  711 17.6
5%   68  1.7
Undiluted mother tincture    3  0.1
aIncluding preparations of Bryophyllum plants grown in the presence of metal dilutions (see text).
bDried press juice mixed with lactose.
cD2 and D3.
dUndiluted, 5%, D2, D3, D4, D5, D6, D8, and D10.
eAqueous solution.
*Prepared exclusively from the species B. pinnatum.
**Prepared from the species B. daigremontianum.
Table 1. Prescribed 
Bryophyllum prepa-
rations 
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Table 2. Prescribing pattern of Bryophyllum preparations according to ICD-10 diagnosis groups in the various gender and age groups
ICD-10  
group
Designation All 
(n = 4038)
Gender Age, years
female 
(n = 2904)
male 
(n = 1134)
< 12 
(n = 1260)
12–29 
(n = 235)
30–44 
(n = 865)
45–59
(n = 1130)
60–79 
(n = 500)
≥ 80 
(n = 48)
C00–D48 neoplasms 1.6 1.7 1.2 < 1 < 1 < 1 3.5 4.4 < 1
D50–D90 diseases of the blood 
and blood-forming 
organs and certain 
disorders involving 
the immune  
mechanism
< 1 < 1 < 1 1.0 < 1 < 1 < 1 < 1 < 1
E00–E99 endocrine,  
nutritional and  
metabolic diseases
1.9 2.4 < 1 < 1 < 1 1.0 2.5 5.6 < 1
F00–F99 mental and  
behavioral disorders
35.7 35.6 35.9 30.5 33.6 34.1 43.3 36.4 25.0
G00–G99 diseases of the  
nervous system
9.7 10.2 8.4 9.9 9.8 8.7 10.2 9.2 14.6
H60–H95 diseases of the ear  
and mastoid process
< 1 < 1 < 1 < 1 < 1 < 1 1.0 1.6 4.2
I00–I99 diseases of the  
circulatory system
3.9 5.0 1.2 < 1 1.3 < 1 3.9 19.8 6.3
J00–J99 diseases of the  
respiratory system
1.7 1.4 2.5 3.4 2.1 < 1 < 1 1.2 2.1
K00–K93 diseases of the  
digestive system
1.7 1.6 2.1 1.0 < 1 2.7 2.4 1.0 < 1
L00–L99 diseases of the skin 
and subcutaneous  
tissue
16.0 13.1 23.4 26.0 20.0 16.9 8.4 5.4 6.3
M00–M99 diseases of the  
musculoskeletal  
system and  
connective tissue
1.0 1.2 < 1 < 1 < 1 < 1 1.8 < 1 2.1
N00–N99 diseases of the  
genitourinary  
system
3.4 4.6 < 1 < 1 2.1 4.4 6.4 3.0 < 1
O00–O99 pregnancy,  
childbirth and the  
puerperium
2.6 3.5 < 1 < 1 < 1 10.6 < 1 < 1 < 1
R00–R99 symptoms, signs and 
abnormal clinical  
and laboratory  
findings, not  
elsewhere classified
15.2 13.5 19.5 21.7 20.9 10.9 11.2 10.6 39.6
S00–T98 injury, poisoning  
and certain other  
consequences of  
external causes
1.1 1.0 1.5 1.1 1.7 1.3 1.2 < 1 < 1
Z00–Z99 factors influencing  
health status and  
contact with health  
services
2.2 2.7 1.0 < 1 3.4 5.2 1.9 < 1 < 1
Data are shown as % of total, only values ≥ 1% are depicted.
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35.7%) and ‘diseases of the skin and subcutaneous tissue’ 
(L00–L99, 16%), followed by ‘symptoms, signs, and abnormal 
clinical and laboratory findings, not elsewhere classified dis-
eases’ (R00–R99, 15.2%) and by ‘diseases of the nervous sys-
tem’ (G00–G99, 9.7%). Table 2 also shows how the focus of the 
prescriptions varied with the age group. In the group younger 
than 12 years, a relatively high number of prescriptions for ‘dis-
eases of the skin and subcutaneous tissue’ and lower use for 
‘mental and behavioral diseases’ was observed. Prescriptions 
for symptoms, signs, and abnormal clinical and laboratory find-
ings, not elsewhere classified diseases were particularly fre-
quent in the case of patients older than 80 years.
Table 3 shows the diagnosis categories corresponding to 
most prescriptions of Bryophyllum preparations taken as a 
whole and to each of the 3 most commonly prescribed mono-
preparations of Bryophyllum plants. In the first case, the fol-
lowing categories corresponded to more than 5% of the total 
prescriptions (table 3): pruritus (L29, 7.4%), sleep disorders 
(G47, 7.3%), depressive episodes (F32, 6.4%), other anxiety 
disorders (F41, 6.3%), symptoms and signs involving emo-
tional state (R45, 5.9%), and atopic dermatitis (L20, 5.2%). 
Somewhat different pictures emerged for the specific prepara-
tions. B. pinnatum 50% powder seemed to be comparatively 
more often prescribed for depressive episodes and recurrent 
depressive disorder, other anxiety disorders, atopic dermatitis, 
essential hypertension, and preterm delivery. In contrast, Bry-
ophyllum Argento cultum Rh (D3 aqueous dilutions) and, 
even more, Bryophyllum Argento cultum (alcoholic dilutions) 
were preferentially prescribed for pruritus. Bryophyllum Ar-
gento cultum Rh (D3 aqueous dilutions) was furthermore re-
latively often prescribed for (organic and non-organic) sleep 
disorders, symptoms and signs involving emotional state, at-
opic dermatitis, and (other) behavioral and emotional diseases 
with onset usually occurring in childhood and adolescence. 
 Besides, for pruritus, Bryophyllum Argento cultum (alcoholic 
dilutions) seemed to be preferentially prescribed for somato-
form disorders, other neurotic diseases, and other dermatitis.
Discussion
More than one third of the documented prescriptions of Bryo-
phyllum preparations aimed at improving ‘mental and behav-
ioral disorders’ (table 2). 3 other diagnosis groups corre-
sponded to at least 10% of the prescriptions, namely 1) ‘skin 
and subcutaneous tissue’, 2) ‘symptoms, signs, and abnormal 
clinical and laboratory findings, not elsewhere classified’, and 
3) ‘diseases of the nervous system’. The frequent prescriptions 
for diagnoses associated with the speciality of psychiatry (F-
diagnoses) even though there were no psychiatrists among 
the participating clinicians were not unexpected since more 
than the half of the participating physicians were general 
practitioners who often prescribe, for instance, antidepres-
sants [27, 28].
most cases (71.9%) female. The majority (53.2%, n = 2,150) 
of the prescriptions were written by general practitioners, 
15.1% (n = 609) by pediatricians, 12.7% (n = 514) by in-
ternists, 10.5% (n = 424) by dermatologists, 6.5% (n = 262) by 
gynecologists, and 2.0% (n = 79) by neurologists. As depicted 
in table 2, a variety of patient age groups were well repre-
sented, even though there was a predominance of young chil-
dren (31.2% of the patients were younger than 12 years) and 
middle-aged adults (28.0% were 45–59 years old). Relatively 
fewer patients were teenagers/young adults (5.8% were 12–29 
years old) or older than 60 years (13.6%).
Prescription Characterization
As shown in table 1, most prescribed preparations had been 
produced with the species B. pinnatum (94.8%), the rest with 
B. daigremotianum. Besides the preparations depicted, a sin-
gle prescription of an additional product was identified, but 
not included in the present analysis (data not shown). The 
majority (77.7%; table 1) of the prescribed preparations were 
produced exclusively from Bryophyllum plants and are in this 
manuscript referred to as ‘Bryophyllum monopreparations’, 
in contrast to the medications prepared with additional sub-
stances, which are referred to as ‘Bryophyllum combinations’. 
A considerable part of the former (those with names compris-
ing the word ‘cultum’, 59.1%) were prepared from the third 
generation of plants whose first generation had been treated 
with dilutions of silver (Argento) or mercury (Mercurio) while 
the second and third generations were manured with the com-
post of the first one. This treatment is characteristic of the an-
throposophic pharmacy and does not result in increased levels 
of the corresponding metals in the treated plants, as shown by 
atomic absorption (Mónica Mennet, personal communica-
tion). 1 preparation included, in addition to Bryophyllum 
plants, a homeopathic dilution of oyster shell (Conchae). B. 
daigremontianum (D3) preparations additionally comprised a 
D5 dilution of silver and a D5 dilution of bovine uterus. 
Whereas the preparations of B. pinnatum were produced 
from fresh leaves, those of B. daigremontianum derive from 
an aqueous mother tincture of leaves that had been submitted 
to a fermentation process according to the technical regula-
tion 33 from the Homeopathic Pharmacopoeia (in German: 
Homöopathisches Arzneimittelbuch, HAB). Finally, the 
preparations Bryophyllum (alcoholic dilutions of the mother 
tincture), Bryophyllum Mercurio cultum (alcoholic dilutions), 
Bryophyllum Rh (D3 aqueous dilutions) and Bryophyllum 
Mercurio cultum Rh (D3 aqueous dilutions) are registered in 
Germany; all remaining ones are officially authorised.
Prescribing Pattern of Bryophyllum Preparations
The diagnoses corresponding to the prescriptions of all Bryo-
phyllum preparations taken together – for all patients accord-
ing to gender and age – are depicted in table 2. Taken as a 
whole, Bryophyllum preparations were most often prescribed 
to treat ‘mental and behavioral disorders’ (block F00–F99, 
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Table 3. Most frequent ICD-10 diagnosis categories for which Bryophyllum preparations were prescribed
ICD-10 Designation All Bryophyllum 
preparations
B. pinnatum 
(50% powder)
Bryophyllum Argento  
cultum Rh (D3 aqueous 
dilutions)
Bryophyllum Argento  
cultum 
(alcoholic dilutions)
n % n % n % n %
L29 pruritus 298 7.4 30 2.8 101 9.6 156 22.5
G47 sleep disorders 296 7.3 60 5.6  99 9.4  37  5.3
F32 depressive episode 257 6.4 76 7.1  18 1.7  42  6.1
F41 other anxiety disorders 254 6.3 99 9.3  29 2.8  33  4.8
R45 symptoms and signs involving  
emotional state
239 5.9 47 4.4  90 8.6  20  2.9
L20 atopic dermatitis 211 5.2 90 8.5  76 7.2  34  4.9
F43 reaction to severe stress and  
adjustment disorders
181 4.5 57 5.4  17 1.6  37  5.3
F33 recurrent depressive disorder 120 3.0 62 5.8  – –  –  –
I10 essential (primary) hypertension 117 2.9 41 3.9  – –  –  –
F45 somatoform disorders 103 2.6 20 1.9  11 1.0  37  5.3
F51 non-organic sleep disorders 103 2.6 22 2.1  66 6.3  11  1.6
R53 malaise and fatigue 103 2.6 13 1.2  12 1.1  18  2.6
F48 other neurotic disorders  71 1.8 17 1.6  – –  19  2.7
L30 other dermatitis  70 1.7 28 2.6  15 1.4  21  3.8
F98 other behavioral and emotional  
disorders with onset usually  
occurring in childhood and  
adolescence
 – – – –  44 4.2  –  –
O60 preterm delivery  – – 30 2.8  – –  –  –
R32 unspecified urinary incontinence  – – – –  26 2.5  –  –
F93 behavioral and emotional  
disorders with onset usually  
occurring in childhood and  
adolescence
 – – – –  23 2.2  –  –
R63 symptoms and signs concerning 
food and fluid intake
 – – – –  21 2.0  –  –
F91 conduct disorders  – – – –  18 1.7  –  –
F81 specific developmental disorders 
of scholastic skills
 – – – –  15 1.4  –  –
J06 acute upper respiratory infections 
of multiple and unspecified sites
 – – – –  13 1.2  –  –
N94 pain and other conditions  
associated with female genital  
organs and menstrual cycle
 – – – –  – –  12  1.7
Z73 problems related to life  
management difficulty
 – – 11 1.0  – –  –  –
R10 abdominal and pelvic pain  – – – –  11 1.0  –  –
F82 specific developmental disorder 
of motor function
 – – – –  10 1.0  –  –
G40 epilepsy  – – – –  10 1.0  –  –
D80 immunodeficiency with  
predominantly antibody defects
 – – – –  – –   9  1.3
F90 hyperkinetic disorders  – – – –  25 2.4   8  1.2
G43 migraine  – – – –  – –   8  1.2
N95 menopausal and other  
perimenopausal disorders
 – – – –  – –   7  1.0
Only diagnoses corresponding to ≥ 1% of the total or of 1 Bryophyllum preparation are shown.
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traction methods are likely to result in different biochemical 
compositions. Whether these and the different concentrations 
can provide a rationale for their different therapeutic use re-
quires further investigations.
Although it is difficult at present to propose a rationale for 
most of the detected uses of Bryophyllum preparations, in 
some cases there is preclinical evidence suggesting therapeu-
tic potential of extracts from leaves of these plants. Their use 
in the treatment of pruritus – whose standard treatment is 
based on antihistamines (H1 antagonists) – is one of these ex-
amples. Press juice of B. pinnatum leaves was shown to pos-
sess antihistamine activity by blocking H1, but not H2, recep-
tors, an effect that has been allocated to a flavonoid fraction 
[36]. Furthermore, an extract from B. pinnatum leaves has 
been shown to down-regulate pro-anaphylactic inducing im-
mune responses [37] and very recently to have potential in the 
treatment of allergic airway disease [38].
Sleep disorders constitute a second example in which pre-
clinical evidence might support the therapeutic use of extracts 
of Bryophyllum. Different fractions of the leaf extract of B. 
pinnatum have been shown to potentiate the pentobarbitone-
induced sleeping time in in vivo models, i.e. to possess a CNS-
depressant action [39]. This neurosedative effect was corrobo-
rated by a later study that in addition revealed muscle-relax-
ant properties of a leaf extract of B. pinnatum [40]. Muscle-
relaxing effects of aqueous extracts from B. pinnatum leaves 
are particularly well-documented in the case of preterm 
uterus contractions both at the clinical level [13] and in vitro, 
using strips of myometrium [14, 15].
Other promising properties of Bryophyllum preparations 
comprise anti-inflammatory and wound-healing effects of B. 
pinnatum leaves [5], which were detected in an in vivo model 
and could justify their use in the treatment of various kinds of 
dermatitis, in particular that of atopic dermatitis, a chronic in-
flammatory skin condition. Moreover, hypotensive properties 
of B. pinnatum leaves have been demonstrated in an in vivo 
model [41].
Conclusion
Bryophyllum preparations were prescribed by physicians par-
ticipating in the EvaMed network for a broad spectrum of 
diagnoses, which is typical for anthroposophic preparations. 
The most frequent diagnosis groups were: 1) ‘mental and be-
havioral disorders’, 2) ‘disorders of skin and subcutaneous 
tissue’, 3) ‘symptoms, signs, and abnormal clinical and labora-
tory findings, not elsewhere classified’, and 4) ‘diseases of the 
nervous system’. Future research should focus on pragmatic 
clinical trials to investigate the effectiveness of Bryophyllum 
preparations in the treatment of the most relevant clinical 
disorders mentioned in this report, in particular of sleep and 
anxiety disorders, as well as of depressions and atopic 
dermatitis.
A major limitation of the present study is the lack of infor-
mation on the tolerability and effectiveness of the treatment 
with the various Bryophyllum preparations. A further limita-
tion of the study is the lack of any information on the daily 
dose and the duration of the application of the Bryophyllum 
preparations. Moreover, the data on the prescribing pattern 
have to be understood in the context of the specialties of the 
physicians participating in the present study: A different phy-
sician group composition would probably have led to a some-
what different weighting of the various diagnoses. Half of the 
participating physicians were general practitioners; therefore, 
this subgroup of physicians most markedly influenced the di-
agnosis spectrum. In the present work, the use of Bryophyl-
lum preparations was not directly compared with that of other 
medications. Assuming, however, that the 4,038 identified 
Bryophyllum prescriptions were written at a homogeneous 
rate during the study period, the number of prescriptions per 
year would be approximately 673, which at least in 2005 [19] 
would correspond to about 0.9% of all prescriptions of an-
throposophic medications. This estimated percentage is mark-
edly inferior to the 9.4% that have been previously reported 
in a prospective cohort study on chronic diseases involving 
131 medical practices in Germany [8]. It is worth noting that 
the physicians were free to prescribe multiple and different 
types of medications for 1 diagnosis. At least in 2005, anthro-
posophic medications corresponded to 41.8% of all medica-
tions prescribed by the physicians participating in this net-
work of anthroposophic physicians, while conventional medi-
cations corresponded to 41.4% of the total [19].
Several components have been identified in leaves from B. 
pinnatum preparations, which are likely to have biological ac-
tivity, namely flavonoid glycosides [29, 30], flavonoids [30–32], 
bufadienolides [33, 34], and phenols [35]. Previous work on 
the pharmaceutical characterization of an aqueous extract di-
rectly obtained from juice of B. pinnatum leaves and identical 
to the starting material to produce each of the three most 
commonly prescribed monopreparations of Bryophyllum 
plants (B. pinnatum 50% powder, Bryophyllum Argento cul-
tum Rh D3 aqueous dilutions and Bryophyllum Argento cul-
tum alcoholic dilutions) revealed the presence of flavonoids, 
cinnamic acid derivatives, and bufadienolides [15]. Even 
though these three preparations have B. pinnatum leaves as 
common plant material, their preparation methods as well as 
the available concentrations are different. The 50% powder is 
produced by mixing press juice of B. pinnatum with the same 
weight of lactose hydrate. In contrast, both preparations of 
Bryophyllum Argento cultum are homeopathic preparations. 
Bryophyllum Argento cultum alcoholic dilutions are produced 
from an alcoholic mother tincture that is homeopathically di-
luted (potentized) to the concentrations D2 (1%) and D3 
(0.1%). Bryophyllum Argento cultum Rh is prepared from an 
aqueous mother tincture produced in a particular process in 
which the extraction temperature is changed rhythmically; 
thereafter, it is potentized at D3 (0.01%). The different ex-
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